VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

10368	Companies
215965	Keywords
145706	Articles
114373	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 04/26/2025 at 19:10, 1 year ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Valneva SE provides an update on the recommendation for the use of its Chikungunya vaccine by French authorities, focusing on adverse events in elderly people. The company is collaborating with regulators on next steps

Valneva SE Chikungunya Vaccine French Authorities Adverse Events Elderly
BRIEF

published on 04/18/2025 at 10:05, 1 year ago

Valneva Updates on Chikungunya Vaccine Recommendation in the U.S.

Valneva Chikungunya Vaccine IXCHIQ® ACIP Recommendation U.S. Travelers
BRIEF

published on 04/18/2025 at 10:05, 1 year ago

Valneva met à jour sa recommandation concernant le vaccin contre le chikungunya aux États-Unis

Valneva Voyageurs Américains Vaccin Contre Le Chikungunya IXCHIQ® Recommandation De L'ACIP
PRESS RELEASE

published on 04/18/2025 at 10:00, 1 year ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring

Valneva CDC Chikungunya Vaccine IXCHIQ® ACIP Recommendation
PRESS RELEASE

published on 04/18/2025 at 10:00, 1 year ago

Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya

Valneva Vaccin Chikungunya IXCHIQ® ACIP
BRIEF

published on 04/09/2025 at 07:05, 1 year ago

Vaccination du premier enfant dans l'étude de Phase 2 sur le vaccin S4V2 contre la shigellose

Valneva Phase 2 Shigellose Vaccin S4V2 Essai Pédiatrique
BRIEF

published on 04/09/2025 at 07:05, 1 year ago

First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva Phase 2 Shigellosis S4V2 Vaccine Pediatric Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 1 year ago

Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2

Valneva Vaccin Shigellose LimmaTech Étude Pédiatrique
PRESS RELEASE

published on 04/09/2025 at 07:00, 1 year ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 03/20/2025 at 07:00, 1 year 1 month ago

Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières

Accesswire

Published on 05/08/2026 at 00:00, 18 minutes ago

Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 48 minutes ago

Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 1 hour 3 minutes ago

BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/07/2026 at 22:05, 2 hours 13 minutes ago

MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications
Published on 05/07/2026 at 22:05, 2 hours 13 minutes ago

Innodata Reports Record First Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 23:23, 54 minutes ago

H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness
Published on 05/07/2026 at 23:14, 1 hour 4 minutes ago

EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved
Published on 05/07/2026 at 22:05, 2 hours 13 minutes ago

Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 3 hours 36 minutes ago

RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 5 hours 32 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 05/07/2026 at 19:15, 5 hours 3 minutes ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 5 hours 3 minutes ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 5 hours 12 minutes ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 5 hours 12 minutes ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 5 hours 18 minutes ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE